Lv1
28 积分 2023-12-11 加入
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial
3天前
已完结
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial
4天前
已完结
A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women
5天前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
1个月前
已完结
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
1个月前
已完结
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
1个月前
已完结
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial
1个月前
已完结
Ribociclib plus Endocrine Therapy in Early Breast Cancer
1个月前
已完结
Cooperative clinical trial of photodynamic therapy with photofrin II and excimer dye laser for early gastric cancer
1个月前
已完结
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
1个月前
已完结
皖公网安备34019202002308
